Chris Viehbacher, Biogen CEO (Photographer: Scott Eells/Bloomberg via Getty Images)
FDA will consult outside advisors on whether Biogen’s ALS drug can be approved on a biomarker
The FDA will ask a panel of outside experts if Biogen’s ALS drug should be approved on the basis of a new neurodegeneration disease biomarker …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
